Pluristem Therapeutics Inc (PSTI)

[Auto1]

TRENDING

PORTFOLIO

PEOPLE

MARKET NEWS

STOCK IDEAS

DIVIDENDS

INVESTING STRATEGY

REITS

WALL STREET BREAKFAST

ON THE MOVE

DIVIDEND NEWS

MARKET OUTLOOK

?

Probio Invest

Follow

Short Ideas

Healthcare 

Israel

Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage

Feb. 02, 2015 4:37 PM ETPluristem Therapeutics Inc. (PSTI)CVM, EVSNF, FLUX...20 Comments

This article is exclusive for subscribers

Summary

Pluristem has a long history of ethically questionable reporting to investors.

Stock price jumps ostensibly on analysis published by a discredited bucket shop.

Heavy dilution is imminent and could have a significant negative effect on the share price.

Top executives have zero educational and professional experience in the biotech field.

The author has not reached out to PSTI management for comments. Phone calls made to Acceleron Equity Research were not returned.

Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases. Since Jan 28th, Pluristem has jumped over 30% on no material news except for one-page coverage update from Acceleron Equity Research.